CGT · 난소암

131개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved131 programs
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 2

CAR-T treatment (CAR-T treatment)

Multiple Myeloma; Relapsed/Refractory · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 1

CAR.B7-H3 (CAR.B7-H3)

Epithelial Ovarian Cancer · B7-H3

#B7-H3#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen University General Hos…Phase 2

CAR/TRuC-T (CAR/TRuC-T)

Relapsed/Refractory B-cell Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleAffiliated Hospital to Academy …Phase 2

CAR2219-T cells (CAR2219-T cells)

Relapsed or Refractory B Cell Leukemia and Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleZhujiang HospitalPreclinical

AML (CART therapy in Acute myeloid leukemia, CART therapy in Acute myeloid leukemia(AML))

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleKite, A Gilead CompanyPhase 1

CART-TnMUC1 (CART-TnMUC1)

Non-Small Cell Lung Cancer; Ovarian Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

CART-meso (CART-meso)

Metastatic Pancreatic (Ductal) Adenocarcinoma; Epithelial Ovarian Cancer · Metastatic Pancreatic (Ductal) Adenocarc

#MetastaticPancreaticDuctalAdenoc#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

CART33 cells (CART33 cells)

Relapsed Adult Myeloid Leukemia; Chemotherapy Refractory Adult Myeloid Leukemia · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleBeijing JD Biotech Co. LTD.Phase 1

CD123-CAR-NK cells (CD123-CAR-NK cells)

Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia Recurrent · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleUniversity of Colorado, DenverPhase 1

CD64 CAR T Cells (CD64 CAR T Cells)

Refractory Acute Myeloid Leukemia (AML); Relapsed Acute Myeloid Leukemia (AML) · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

CD70 CAR-NK (CD70 CAR-NK)

Relapsed/Refractory T-cell Lymphoma; Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Preclinical

CT0590 CAR T Cells (CT0590 CAR T Cells)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMEI HENGPhase 1

CT0991 CAR-T cells infusicn (CT0991 CAR-T cells infusicn)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

CXCR4 CCR9 CAR-T (CXCR4 CCR9 CAR-T)

Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleCaribou Biosciences, Inc.Preclinical

Caribou-sponsored investigational therapy (Caribou-sponsored investigational therapy)

Lymphoma, Non-Hodgkin; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleJennifer Crombie, MDPhase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) Therapy Infusion)

Primary Mediastinal Large B-cell Lymphoma (PMBCL); Primary Mediastinal Large B Cell Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNelson HamerschlakPhase 1

Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 (Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital of G…Phase 1

Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells (Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells)

Stage IV Ovarian Cancer; Testis Cancer, Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleWashington University School of…Phase 2

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleCartesian TherapeuticsPhase 1

Descartes-15 (Descartes-15)

Refractory Multiple Myeloma; Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued

4 / 7 pages

← PreviousNext →